Description
The Global Parenteral Nutrition Market size was USD $7.11 billion in 2023 and is projected to reach USD $9.2 billion by 2031, with a CAGR of 6.5 % during the forecast period.
Parenteral Nutrition Market: Overview
The global parenteral nutrition market has witnessed notable innovations aimed at improving patient outcomes and addressing specific needs. One such advancement is the use of fatty acids from fish oil triglycerides, particularly in elderly populations, to enhance liver function and boost plasma platelet count, thus aiding in glucose restoration and nutritional support for post-surgical patients. Baxter International Inc. has introduced olive oil-based parenteral nutrition solutions, providing a ready-to-use option for high-stress patients. Additionally, personalized nutritional solutions have emerged, tailoring parenteral nutrition to the unique requirements of individual patients to optimize outcomes. Intelligent infusion devices are another significant development, featuring dose error reduction software, wireless connectivity, and customizable settings to enhance safety and precision in administration. The introduction of new lipid injectable emulsions (LIEs) offers essential fatty acids and energy while improving patient tolerance and minimizing complications. Furthermore, innovative amino acid solutions have been developed for patients with specific needs, such as those with liver disease, renal impairment, or metabolic disorders, aiming to optimize nitrogen balance and support protein synthesis. These advancements collectively enhance patient care and are expected to drive future growth in the parenteral nutrition industry.
Parenteral Nutrition Market Dynamics:
-
Growth Drivers:
1. Increasing incidence of chronic diseases
The rise in chronic diseases such as cancer, gastrointestinal disorders, and renal failures has significantly boosted the demand for parenteral nutrition. Patients with these conditions often require specialized nutrition that cannot be provided through traditional oral intake. Parenteral nutrition offers a vital solution, ensuring that patients receive the essential nutrients directly into their bloodstream, bypassing the digestive tract. This method is critical for those who are unable to absorb nutrients adequately due to their medical conditions. As the prevalence of chronic illnesses increases globally, the need for parenteral nutrition is expected to grow correspondingly.
2. Advancements in parenteral nutrition formulations
Technological advancements in parenteral nutrition formulations have greatly enhanced the effectiveness and safety of these products. Innovations such as personalized nutrition plans, improved nutrient compositions, and advanced delivery systems have made parenteral nutrition more accessible and effective. These advancements ensure better patient outcomes by providing tailored nutrition solutions that meet the specific needs of individual patients. As research and development continue to evolve, the quality and variety of parenteral nutrition products are expected to improve, driving further market growth.
3. Rising geriatric population
The global increase in the geriatric population is a significant driver for the parenteral nutrition market. Older adults often face age-related health issues that can impair their ability to consume or absorb nutrients efficiently. Conditions such as malnutrition, chronic diseases, and surgical recovery in the elderly require specialized nutritional support. Parenteral nutrition provides a critical solution for maintaining optimal health and managing complex medical conditions in elderly patients. The growing number of aging individuals will likely drive continued demand for parenteral nutrition services and products.
-
Restraining Factor:
1. Risk of complications
Parenteral nutrition carries inherent risks and potential complications such as infections, thrombosis, and metabolic imbalances. These complications can result from the intravenous administration of nutrients and require careful management and monitoring. The risk of such adverse effects may deter some healthcare providers from recommending parenteral nutrition, especially when alternative methods are available. Managing these risks effectively requires significant resources and expertise, which can constrain market growth and adoption.
-
Opportunity Factors:
1. Expansion in emerging markets
There is significant growth potential for the parenteral nutrition market in emerging economies. As these regions develop their healthcare infrastructure and increase their focus on advanced medical treatments, the demand for parenteral nutrition is likely to rise. Improved access to healthcare services and rising awareness about the benefits of specialized nutrition will drive market expansion in these areas. Companies entering these markets can benefit from untapped opportunities and increased patient populations requiring advanced nutritional solutions.
2. Development of home parenteral nutrition programs
The growing trend towards home healthcare presents a unique opportunity for expanding parenteral nutrition services. Home parenteral nutrition (HPN) programs enable patients to receive nutrition in the comfort of their homes, reducing hospital stays and improving quality of life. Advances in technology and patient education are making home-based nutrition programs more feasible and safer. This shift towards home care solutions could increase the adoption of parenteral nutrition and drive market growth by providing more convenient and personalized care options for patients.
Parenteral Nutrition Market: Segmentation
By Nutrient Type:
- Carbohydrates
- Parenteral Lipid Emulsion
- Single Dose Amino Acid Solution
- Trace Elements
- Vitamins & Minerals
By Stage Type:
- Adult
- Paediatrics
By Indication:
- Alzheimer’s
- Nutrition Deficiency
- Cancer Care
- Diabetes
- Chronic Kidney Diseases
- Orphan Diseases
- Dysphagia
- Pain Management
- Malabsorption/GI Disorder/Diarrhoea
- Others
By Sales Channel:
- Online
- Retail
- Institutional
Parenteral Nutrition Market: Regional Insights
North America dominated the global parenteral nutrition market, by region. The North American parenteral nutrition market is experiencing robust growth due to increasing prevalence of chronic diseases, rising geriatric population, and advancements in nutritional products. Parenteral nutrition, which involves delivering nutrients directly into the bloodstream, is crucial for patients who cannot consume food orally or absorb nutrients through the digestive tract. In North America, the market is driven by the growing demand for personalized nutrition solutions, technological innovations in nutrient delivery systems, and rising awareness about the benefits of parenteral nutrition in managing complex medical conditions. Additionally, the expansion of healthcare infrastructure and increasing healthcare expenditure contribute to market growth. Key players in the region are focusing on enhancing product offerings and expanding their distribution networks to meet the diverse needs of healthcare providers and patients. The market’s dynamics are further influenced by regulatory advancements and the ongoing research and development activities aimed at improving the efficacy and safety of parenteral nutrition products.
Asia Pacific is expected to grow at the highest CAGR in the global parenteral nutrition market, during forecast period. The Asia Pacific Parenteral Nutrition Market is experiencing significant growth due to increasing prevalence of chronic diseases, a rise in the geriatric population, and advancements in medical technology. Parenteral nutrition, which involves the intravenous administration of nutrients, is crucial for patients unable to receive adequate nutrition through oral or enteral means. The market’s expansion is driven by rising healthcare expenditure, improving healthcare infrastructure, and growing awareness about nutritional support in managing complex medical conditions. Key factors influencing the market include the increasing incidence of conditions such as cancer, gastrointestinal disorders, and severe malnutrition, coupled with technological innovations that enhance the efficacy and safety of parenteral nutrition products. Additionally, the expanding network of healthcare facilities and increasing government initiatives to support healthcare advancements are contributing to the market’s growth. As the demand for personalized and precise nutritional solutions increases, the Asia Pacific Parenteral Nutrition Market is poised for continued development, with major players focusing on research and development to meet evolving healthcare needs.
Parenteral Nutrition Market: Key Players
- Baxter
- Grifols, S.A.
- Allergan
- Otsuka Pharmaceutical Factory, Inc.
- Actavis Inc.
- Braun Melsungen AG
- Fresenius Kabi AG
- Vifor Pharma
- Sichuan Kelun Pharmaceutical Co., Ltd.
- Pfizer Inc. (Hospira Inc.)
Parenteral Nutrition Market: Recent Developments
- In August 2024, Ntense Injection and Ntense EF Injection, two high amino acid nutritional fluids, were introduced by Fresenius Kabi Korea. Ntense, which stands for “Nitrogen intensify,” is an amino acid-based three-chamber bag that offers the necessary protein-to-calorie ratio (1.5g:20kcal) and nutritional support for critically ill patients who are at high risk of muscle wasting even during brief hospital stays.
- In January 2024, In the United States, a new zinc sulphate injection USP concentration of 10 mg/10 mL (1 mg/mL) has been introduced by Piramal Pharma’s division, Piramal Critical Care (PCC). With the introduction, PCC will be able to grow both the portfolio of generic injectables as a whole and their current Zinc Sulphate Injection product line. When oral or enteral nutrition is not feasible, insufficient, or inappropriate, zinc sulphate is a trace element that can be used to provide zinc to patients, both adult and paediatric.
- In August 2022, the first-to-market generic launch of zinc sulphate injection in the United States has been announced by Piramal Pharma’s Critical Care division, a prominent provider of complex hospital generics. With the Competitive Generic Therapy (CGT) classification, this medicine has received approval from the US Food and Drug Administration. This certification process aims to increase market competition for drugs sourced from exclusive sources.